|Bid||0.00 x 900|
|Ask||0.00 x 1300|
|Day's range||383.82 - 391.87|
|52-week range||298.69 - 401.78|
|Beta (5Y monthly)||0.58|
|PE ratio (TTM)||15.54|
|Earnings date||01 Aug 2023 - 07 Aug 2023|
|Forward dividend & yield||2.16 (0.56%)|
|Ex-dividend date||31 May 2023|
|1y target est||445.54|
McKesson (MCK) closed at $389.22 in the latest trading session, marking a +1.2% move from the prior day.
IRVING, Texas, June 07, 2023--McKesson Corporation (NYSE:MCK) (the "Company") today announced that it has commenced an offer to purchase for cash (the "Tender Offer") any and all of its outstanding 3.796% Notes due 2024 (the "2024 Notes"). The Tender Offer is being made pursuant to the terms and subject to the conditions set forth in the Offer to Purchase, dated as of June 7, 2023 (the "Offer to Purchase") and the related notice of guaranteed delivery (together with the Offer to Purchase, the "O
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
A big allure of investing in healthcare is that the industry tends to have stocks stable enough to provide you with some long-term safety. Given that the need for healthcare will only grow with an aging population, the industry is also home to some solid growth stocks. Three relatively safe healthcare stocks that have doubled in value over the past five years include Thermo Fisher Scientific (NYSE: TMO), McKesson (NYSE: MCK), and Intuitive Surgical (NASDAQ: ISRG).
McKesson (NYSE: MCK) is one of the largest pharmaceutical distributors in the country. While this isn't the type of investment you might expect 10x returns from, it can provide stability and even reliable dividend income. On the first day of trading in 2018, shares of McKesson closed at $159.
You may know Pfizer (NYSE: PFE) for its blockbuster coronavirus vaccine. Pfizer may face a bit of a near-term slowdown in revenue. In fact, Pfizer says these launches should result in $20 billion in sales in 2030.
This company is the largest player in the medical distribution industry and is featured in Berkshire Hathaway's investment portfolio.
You don't have to worry about pinpointing an entry point if the underlying company is truly built to last.
McKesson's (MCK) fiscal fourth-quarter 2023 results benefit from growth in the United States. Divestment hurt the International segment.
It has been said many times before, and it will be many times again: Warren Buffett is the greatest investor of all time. Among the many world-class businesses in Berkshire Hathaway's $345.4 billion investment portfolio, here are two that I think dividend growth investors should strongly consider buying this month. It's no secret that Buffett and his business partner Charlie Munger prefer to invest in businesses that are profitable and possess competitive moats.
At this time, I would like to turn the call over to Nicole Kramer, manager of investor relations. Today, I'm joined by Brian Tyler, our chief executive officer; and Britt Vitalone, our chief financial officer.
The headline numbers for McKesson (MCK) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
McKesson (MCK) delivered earnings and revenue surprises of 0.42% and 1.08%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
IRVING, Texas, May 08, 2023--McKesson Corporation (NYSE: MCK) has released its fiscal 2023 fourth-quarter financial results. Results can be accessed on McKesson’s Investor Relations website at investor.mckesson.com/financials/quarterly-results.
Inter Parfums' (IPAR) Q1 earnings are expected to reflect gains from robust top-line growth, strength across brands, expansions and product launches.
McKesson's (MCK) fiscal fourth-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
The COVID-19 public health emergency is slated to end in the U.S. on May 11. Three of the best-performing healthcare stocks since then include Moderna (NASDAQ: MRNA), McKesson (NYSE: MCK), and Eli Lilly (NYSE: LLY). It has multiple products in its approval pipeline, including a vaccine for the respiratory syncytial virus that has been highly effective in late-stage trials.
Staar Surgical (STAA) delivered earnings and revenue surprises of 63.64% and 10.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
In the latest trading session, McKesson (MCK) closed at $361, marking a +1.97% move from the previous day.
SmileDirectClub (SDC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardinal Health's (CAH) third-quarter fiscal 2023 results are expected to reflect solid performance in the Pharmaceutical segment. However, inflationary pressure is likely to have continued.
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
The healthcare industry is a great place to find stocks that can perform well under any economic conditions.
DENTSPLY SIRONA's (XRAY) first-quarter 2023 results are likely to reflect strong performance in the Technologies & Equipment business.